Year archive

Bioversys N — 2025 filings

All 48 regulatory filings released by Bioversys N (BIOV) in 2025, sourced directly from the official regulator.

48 Filings

2025 Period

2025 filings (48)

Filing	Released	Lang
BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update Regulatory Filings	2025-12-11	English
BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update Regulatory Filings	2025-12-11	English
BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network Regulatory Filings	2025-11-10	English
BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network Regulatory Filings	2025-11-10	English
Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA Regulatory Filings	2025-11-06	English
Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA Regulatory Filings	2025-11-06	English
Bioversys to Present at Stifel 2025 Annual Healthcare Conference in New york Regulatory Filings	2025-11-05	English
Bioversys to Present at Stifel 2025 Annual Healthcare Conference in New york Report Publication Announcement	2025-11-05	English
Bioversys announces appointment of anti-infective expert Dr. Daniel Ritz as Chief Scientific Officer and retirement of Dr. Sergio Lociuro Board/Management Information	2025-11-03	English
Bioversys announces appointment of anti-infective expert Dr. Daniel Ritz as Chief Scientific Officer and retirement of Dr. Sergio Lociuro Board/Management Information	2025-11-03	English
Bioversys reports corporate highlights and key financials for the first half 2025 Earnings Release H1 2025	2025-09-10	English
Bioversys reports corporate highlights and key financials for the first half 2025 Earnings Release H1 2025	2025-09-10	English
BioVersys Half Year Report 2025 Interim / Quarterly Report H1 2025	2025-09-10	English
BioVersys receives EMA Orphan Designation for the combination of alpibectir and ethionamide for the treatment of tuberculosis Regulatory Filings	2025-08-27	English
BioVersys receives EMA Orphan Designation for the combination of alpibectir and ethionamide for the treatment of tuberculosis Regulatory Filings	2025-08-27	English
Commercial register Regulatory Filings	2025-07-10	English
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOUS MYCOBACTERIA (NTM) CLINICAL CANDIDATE Regulatory Filings	2025-07-02	English
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOUS MYCOBACTERIA (NTM) CLINICAL CANDIDATE M&A Activity	2025-07-02	English
BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS AGM Information	2025-06-30	English
BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS AGM Information	2025-06-30	English
Article of Association AGM Information	2025-06-27	English
BioVersys publishes Invitation to its ANNUAL GENERAL MEETING OF SHAREHOLDERS 2025 AGM Information	2025-06-03	English
BioVersys publishes Invitation to its ANNUAL GENERAL MEETING OF SHAREHOLDERS 2025 AGM Information	2025-06-03	English
BioVersys Corporate Presentation Investor Presentation	2025-04-30	English
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter on May 7, 2025 Regulatory Filings	2025-04-28	English
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter on May 7, 2025 Report Publication Announcement	2025-04-28	English
BIOVERSYS TO PRESENT BV100 PHASE 2 DATA AT 35TH ESCMID GLOBAL 2025 Regulatory Filings	2025-04-08	English
BIOVERSYS ANNOUNCES IMPORTANT BV100 PATENT GRANTED BY CHINESE PATENT OFFICE Regulatory Filings	2025-03-31	English
BIOVERSYS REPORTS CORPORATE HIGHLIGHTS AND KEY FINANCIALS FOR THE FULL YEAR 2024 Earnings Release FY 2024	2025-03-27	English
Webcast Financial Results 2024 & Business update Regulatory Filings	2025-03-27	English
BIOVERSYS REPORTS CORPORATE HIGHLIGHS AND KEY FINANCIALS FOR THE FULL YEAR 2024 Earnings Release FY 2024	2025-03-26	English
BIOVERSYS REPORTS CORPORATE HIGHLIGHS AND KEY FINANCIALS FOR THE FULL YEAR 2024 Earnings Release FY 2024	2025-03-26	English
BioVersys Annual Report 2024 Annual Report FY 2024	2025-03-26	English
FIRST EVER PATIENT DOSED WITH ALPIBECTIR-ETHIONAMIDE IN COMBINATION WITH FIRST-LINE TB DRUGS IN A 14-DAY PHASE 2 CLINICAL TRIAL Legal Proceedings Report	2025-03-20	English
FIRST EVER PATIENT DOSED WITH ALPIBECTIR-ETHIONAMIDE IN COMBINATION WITH FIRST-LINE TB DRUGS IN A 14-DAY PHASE 2 CLINICAL TRIAL Legal Proceedings Report	2025-03-19	English
BIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVENT DETAILS Report Publication Announcement	2025-03-14	English
BIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVENT DETAILS Report Publication Announcement	2025-03-14	English
Bioversys announces partial exercise of over-allotment option Share Issue/Capital Change	2025-03-11	English
Bioversys announces partial exercise of over-allotment option Share Issue/Capital Change	2025-03-10	English
Bioversys announces partial exercise of over-allotment option Share Issue/Capital Change	2025-03-10	English
Charter of the Audit and Risk Committee BioVersys AG Governance Information	2025-03-01	English
Charter of the Compensation and Nomination Committee BioVersys AG Governance Information	2025-02-28	English
Disclosure, Reporting and Trading Policy BioVersys AG Governance Information	2025-02-28	English
Organizational Regulations of BioVersys AG Governance Information	2025-02-28	English
Charter of the Audit and Risk Committee BioVersys AG Governance Information	2025-02-28	English
Commercial register Board/Management Information	2025-02-13	German
BIOVERSYS SUCCESSFULLY ADVANCES BV500 NTM PROGRAM WITH CONTINUED SUPPORT FROM CF AMR SYNDICATE Regulatory Filings	2025-02-11	English
BIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025 Share Issue/Capital Change	2025-02-06	English